Replies to post #202580 on Biotech Values

[lgonber]

JUNO. Well, that was fast. I had buy orders for both JUNO and KITE but didn't get filled. They were a bit lower to yesterday´s close. I was expecting a quick FDA response and lift but not that quick! Congrats to those who added after the news of trial stopped. I keep my JUNO IPO shares for the moment though.

[DewDiligence]

JUNO acquires (private) RedoxTherapies for $10M plus contingencies:

http://www.businesswire.com/news/home/20160714006263/en/Juno-Therapeutics-Adds-Adenosine-Receptor-Antagonist-Acquisition

Juno Therapeutics, Inc...announced today that it has acquired RedoxTherapies, Inc., a privately held company based in Boston, Massachusetts. The acquisition provides Juno with an exclusive license to vipadenant, a small molecule adenosine A2a (A2a) receptor antagonist that has the potential to disrupt important immunosuppressive pathways in the tumor microenvironment in certain cancers. Juno intends to explore this molecule in combination with its engineered T cell platform and may over time explore it in other areas as well.